Published Date: 08 Mar 2023
A positive relationship between social interaction and survival was detected regardless of underlying health conditions, suggesting that clinicians should recommend daily social interactions for all older individuals.
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 6, 2026.
A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.
A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.
The single-arm CLAD-MAPET study is evaluating whether cladribine tablets reduce microglial activation, captured by [F-18]PBR06-PET, in patients with MS experiencing progression without relapse or MRI activity on anti-CD20 therapy.
Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD
The HCPFive: Top News for Healthcare Providers from the Week of 02/01
HCPLive 5 Stories in Under 5: Week of 02/01
1.
Having a tattoo could increase your risk of developing lymphoma.
2.
An individual state lost $4.02 billion due to untreated mental illness.
3.
Novel biomarker has potential for predicting and treating skin cancer metastasis
4.
Adopted cancer cells and the effects of their presence.
5.
A new therapeutic approach could help tackle radiation resistance in childhood brain tumors
1.
Genetic Screening: A Game Changer in Cancer Prevention
2.
Evolving Cancer Treatments: Innovations, Success Rates, and Mechanisms
3.
Radiation Oncology Advances: Guidelines, Trials, Digital Tools & Education
4.
Exploring the Causes and Treatments of Bacterial Keratitis: A Comprehensive Guide
5.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part V
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation